Want to see KRRO full AI Analyst Report?
KRRO Stock Chart & Stats
$14.39
-$1.03(-2.68%)
At close: 4:00 PM EST
$14.39
-$1.03(-2.68%)
Day’s Range― - ―
52-Week Range$5.20 - $55.89
Previous CloseN/A
Volume28.02K
Average Volume (3M)734.66K
Market Cap
$201.92M
Enterprise Value$91.17M
Total Cash (Recent Filing)$113.97M
Total Debt (Recent Filing)$42.88M
Price to Earnings (P/E)―
Beta2.85
Next Earnings
Aug 18, 2026EPS Estimate
-1.34Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-11.68
Shares Outstanding14,422,571
10 Day Avg. Volume1,808,258
30 Day Avg. Volume734,659
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)1.46
Price to Sales (P/S)11.77
P/FCF Ratio-0.95
Enterprise Value/Market Cap0.45
Enterprise Value/Revenue23.73
Enterprise Value/Gross Profit32.41
Enterprise Value/Ebitda-1.17
Forecast
1Y Price Target
$19.00Price Target Upside32.04% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)-5.32
Revenue Forecast (FY)$1.68M
Bulls Say, Bears Say
Bulls Say
Pipeline Advancement (KRRO-111)Selection of KRRO-111 with very strong PiZZ preclinical readouts is a structural positive: it meaningfully expands Korro’s pipeline in liver-delivered RNA editing, strengthens its technology validation, and increases the probability of durable partnerships or milestone revenue as programs advance through IND-enabling work and clinical stages.
High Reported Gross MarginA reported TTM gross margin near 83% suggests the company’s platform can be high-margin at scale or under licensing arrangements. Structurally, high product/royalty economics improve long-term operating leverage once development converts to partnered or commercial revenues, supporting sustainable profitability potential if programs succeed.
Manageable Leverage And Balance-sheet CapacityModerate leverage and a sizeable asset base provide near-term balance-sheet capacity to fund R&D and program advancement without immediate distress. Structurally, this reduces short-term refinancing urgency and supports execution of clinical/development milestones that can unlock non-dilutive or partnership financing over the next several quarters.
Bears Say
Large Cash BurnSustained negative operating and free cash flow of roughly -$70M TTM is a structural weakness: ongoing high cash burn will necessitate repeated financing or partnership monetization, increasing dilution risk and potentially constraining strategic choices if capital markets or deal opportunities tighten over the next several quarters.
Small, Declining Revenue BaseVery low and declining revenues impair the company’s ability to offset R&D and G&A spending. Structurally, uneven partnering and minimal recurring revenue reduce visibility into sustainable cash inflows, forcing reliance on external funding or milestone-driven payments to progress multiple development programs.
Persistent Losses And Weak ReturnsMaterial operating and net losses with sharply negative returns and historical balance-sheet volatility indicate structural profitability challenges. Over months, continued unprofitability raises the likelihood of dilution, restructurings, or constrained R&D prioritization, which can hinder long-term program execution and shareholder value creation.
Korro Bio News
KRRO FAQ
What was Korro Bio’s price range in the past 12 months?
Korro Bio lowest stock price was $5.20 and its highest was $55.89 in the past 12 months.
What is Korro Bio’s market cap?
Korro Bio’s market cap is $201.92M.
When is Korro Bio’s upcoming earnings report date?
Korro Bio’s upcoming earnings report date is Aug 18, 2026 which is in 46 days.
How were Korro Bio’s earnings last quarter?
Korro Bio released its earnings results on May 07, 2026. The company reported -$1.69 earnings per share for the quarter, beating the consensus estimate of -$1.727 by $0.037.
Is Korro Bio overvalued?
According to Wall Street analysts Korro Bio’s price is currently Undervalued.
Does Korro Bio pay dividends?
Korro Bio does not currently pay dividends.
What is Korro Bio’s EPS estimate?
Korro Bio’s EPS estimate is -1.34.
How many shares outstanding does Korro Bio have?
Korro Bio has 14,422,571 shares outstanding.
What happened to Korro Bio’s price movement after its last earnings report?
Korro Bio reported an EPS of -$1.69 in its last earnings report, beating expectations of -$1.727. Following the earnings report the stock price went down -3.373%.
Which hedge fund is a major shareholder of Korro Bio?
Currently, no hedge funds are holding shares in KRRO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Korro Bio Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$19.00 (32.04% Upside)
$19.00 (32.04% Upside)
Hedge Fund Trend
Increased
By 409.3K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▲ 0.5%
Last 30 Days ▲ 3.1%
Last 30 Days ▲ 3.1%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-88.72%
12-Months-Change
Fundamentals
Return on Equity
-117.86%
Trailing 12-Months
Asset Growth
-9.19%
Trailing 12-Months
Company Description
Korro Bio
Korro Bio, Inc., a biopharmaceutical firm based in Cambridge, Massachusetts, is dedicated to exploring, advancing, and bringing to market genetic therapeutics. These treatments are formulated through RNA editing technology, aiming to address a wide array of medical conditions, encompassing both uncommon and widespread diseases.
KRRO Stock 12 Month Forecast
Average Price Target
$19.00
▲(32.04% Upside)
Technical Analysis
Assembly Biosciences
―
Annexon Biosciences
―
4D Molecular Therapeutics
―
Design Therapeutics
―
Aura Biosciences Inc
―